필그라스팀 및 바이오시밀러 시장 : 시장 예측(2026-2032년)

The Filgrastim & Biosimilars Market is projected to grow by USD 4.02 billion at a CAGR of 15.67% by 2032.

Filgrastim and Biosimilars: Executive Market Context

Filgrastim is a recombinant granulocyte colony-stimulating factor used to reduce the duration of neutropenia and the risk of infection associated with myelosuppressive chemotherapy and other clinical settings. Biosimilars have expanded the therapeutic field by introducing additional sources of supply and supporting more structured approaches to biologic procurement. Market development is shaped by clinical confidence, regulatory comparability standards, hospital protocols, reimbursement design, manufacturing reliability, and treatment access.

How Competition and Procurement Are Reshaping Filgrastim Use

The landscape is shifting from reliance on individual biologic brands toward multi-source purchasing and evidence-based substitution policies. Hospitals and public health systems are placing greater emphasis on total treatment cost, supply continuity, interchangeability rules, cold-chain execution, and pharmacovigilance. These changes favor suppliers able to demonstrate consistent quality, dependable distribution, and practical support for clinicians and pharmacists while preserving patient confidence in biosimilar use.

Artificial Intelligence Is Improving Demand, Safety, and Supply Decisions

Artificial intelligence can strengthen filgrastim planning by analyzing treatment schedules, inventory movements, utilization patterns, and adverse-event reports. Predictive tools may help providers identify likely demand peaks, reduce avoidable stockouts, and prioritize replenishment across distributed care networks. In clinical operations, AI-assisted decision support can support risk stratification and protocol monitoring, but its outputs require validation, human oversight, strong data governance, and compliance with applicable health-data and medical-device requirements.

Regional Insights Across Six Healthcare Landscapes

North America is characterized by sophisticated oncology infrastructure, payer scrutiny, and detailed biologic substitution processes. Europe emphasizes centralized assessment, national reimbursement decisions, and biosimilar adoption within cost-conscious health systems. Asia-Pacific combines expanding oncology capacity with highly varied regulatory and reimbursement environments. Latin America is influenced by public procurement, import dependence, and uneven access between major urban centers and broader populations. The Middle East is investing in specialized care and local health-system capacity, while procurement coordination and regulatory maturity vary across markets. Africa continues to face access, affordability, diagnostic, and supply-chain constraints, making reliable distribution and appropriately designed public-health procurement especially important.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN presents a diverse set of regulatory pathways, healthcare budgets, and manufacturing capabilities, creating opportunities for regionally adaptable access models. BRICS economies combine substantial patient needs with differing approaches to domestic production, public procurement, and regulatory review. The European Union benefits from aligned scientific and regulatory principles, although national reimbursement and hospital purchasing decisions remain distinct. G7 systems generally combine advanced oncology services with stringent evidence, safety, and budget requirements. GCC countries are strengthening specialized healthcare capacity and often use coordinated procurement approaches, while NATO members span mature and emerging health systems whose preparedness priorities can increase attention to resilient pharmaceutical supply chains.

Country-Level Priorities for Access, Regulation, and Supply

Australia and Canada face the practical challenge of serving geographically dispersed populations through coordinated reimbursement and distribution. Brazil and Mexico must balance public-sector procurement, local access, and regional disparities. China and India combine large treatment needs with evolving regulatory frameworks and growing interest in domestic biopharmaceutical capability. France, Germany, Italy, Spain, and the United Kingdom continue to evaluate biosimilar uptake through national or regional purchasing, prescribing, and substitution policies. Japan emphasizes rigorous quality expectations and structured reimbursement management. South Korea is developing advanced biologic manufacturing and healthcare capabilities. Russia's environment is shaped by domestic supply priorities and changing access conditions. The United States remains focused on interchangeability, payer policy, provider adoption, and supply resilience.

Practical Priorities for Leaders in Filgrastim Access and Delivery

Industry leaders should build a resilient, multi-source supply strategy supported by qualified manufacturing capacity, redundant logistics, and transparent shortage-monitoring processes. Clinical adoption can be strengthened through clear comparability evidence, clinician and pharmacist education, and patient-centered communication that explains biosimilar quality and treatment continuity. Organizations should tailor contracting and reimbursement approaches to local rules, measure switching and persistence outcomes, and maintain robust pharmacovigilance. Investment in interoperable data systems and carefully governed AI can improve demand planning, while partnerships with health systems can help extend access without compromising quality.

Research Methodology for the Executive Assessment

This assessment uses the supplied market scope-filgrastim and its biosimilars-and organizes findings around regulatory, clinical, procurement, manufacturing, access, and technology drivers. Insights are synthesized from established characteristics of biologic medicines, biosimilar development, oncology-supportive care, healthcare purchasing, and regional health-system variation. Regional, group, and country observations are presented as qualitative context rather than numerical estimates. No market sizing, market-share calculations, forecasts, or company-specific claims are included.

Conclusion: Access and Reliability Will Define Competitive Strength

Filgrastim and biosimilars are positioned at the intersection of oncology demand, biologic competition, healthcare affordability, and supply-chain resilience. Success will depend less on product availability alone than on credible evidence, consistent manufacturing, effective substitution support, dependable distribution, and alignment with local reimbursement systems. Leaders that combine operational resilience with responsible digital innovation and clear stakeholder engagement will be better placed to improve continuity of care and broaden access across diverse health markets.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Filgrastim & Biosimilars Market, by Product Type

• 7.1. Introduction
• 7.2. Biosimilar Filgrastim
  • 7.2.1. Accofil
  • 7.2.2. Nivestim
  • 7.2.3. Zarxio
• 7.3. Originator Filgrastim

8. Filgrastim & Biosimilars Market, by Dosage Form

• 8.1. Introduction
• 8.2. Prefilled Syringe
• 8.3. Vial

9. Filgrastim & Biosimilars Market, by Strength

• 9.1. Introduction
• 9.2. 300 Microgram
• 9.3. 480 Microgram

10. Filgrastim & Biosimilars Market, by Application

• 10.1. Introduction
• 10.2. Chemotherapy Induced Neutropenia
  • 10.2.1. Hematologic Malignancy Treatment
  • 10.2.2. Solid Tumor Treatment
• 10.3. Severe Chronic Neutropenia
• 10.4. Stem Cell Mobilization

11. Filgrastim & Biosimilars Market, by End User

• 11.1. Introduction
• 11.2. Homecare
• 11.3. Hospital
• 11.4. Specialty Clinic

12. Filgrastim & Biosimilars Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacy
• 12.3. Online Pharmacy
• 12.4. Retail Pharmacy

13. Filgrastim & Biosimilars Market, by Region

• 13.1. Introduction
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Europe
• 13.6. Middle East
• 13.7. Africa

14. Filgrastim & Biosimilars Market, by Group

• 14.1. Introduction
• 14.2. ASEAN
• 14.3. GCC
• 14.4. European Union
• 14.5. BRICS
• 14.6. G7
• 14.7. NATO

15. Filgrastim & Biosimilars Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Canada
• 15.4. Mexico
• 15.5. Brazil
• 15.6. United Kingdom
• 15.7. Germany
• 15.8. France
• 15.9. Russia
• 15.10. Italy
• 15.11. Spain
• 15.12. China
• 15.13. India
• 15.14. Japan
• 15.15. Australia
• 15.16. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Amgen Inc.
• 17.2. Apotex Inc.
• 17.3. Biocon Biologics Ltd.
• 17.4. Celltrion Inc.
• 17.5. Fresenius Kabi AG
• 17.6. Intas Pharmaceuticals Ltd.
• 17.7. Kyowa Kirin Co. Ltd.
• 17.8. Pfizer Inc.
• 17.9. Sandoz International GmbH
• 17.10. Teva Pharmaceutical Industries Ltd.
• 17.11. Viatris Inc.

18. Key Experts